Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company that developed and commercialized Rezdiffra (resmetirom), the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-severe liver fibrosis. The company is now pursuing expanded indications and next-generation oral small-molecule therapeutics for liver and metabolic diseases.
Company Info
Upcoming Milestones & Key Dates
Q1 2026 Earnings Conference Call and Rezdiffra launch trajectory update
MAESTRO-NASH OUTCOMES Phase 3 readout (cirrhosis F4)
The Liver Meeting (AASLD) — MASH clinical data presentations
Clinical Development Pipeline
Recent News
Madrigal Pharmaceuticals is touring the United States with a giant inflatable liver to raise awareness of MASH (metabolic dysfunction-associated steatohepatitis) and its approved therapy Rezdiffra, the first FDA-approved drug for the disease.
Madrigal Pharmaceuticals' Rezdiffra continues to outperform analyst expectations in the MASH liver disease market, with sales tracking ahead of consensus as the company works to differentiate the first-in-class therapy in an increasingly competitive landscape.
Leadership Team
Careers & Job Openings